Press Coverage

Transforming the Practice of Medicine and the Delivery of Health Care

One Investment at a Time

Biomatics Capital is a for-profit venture firm investing in transformational innovation at the intersection of health care and technology. We don’t do incremental. We like outliers, the big ideas that shake things up.

Data will change healthcare

We are at a tipping point. In the next decade, breakthrough science and technology will fundamentally transform the practice of medicine and delivery of health care. Two types of data — genomics and digital data — are converging to enable better, faster and lower-cost therapeutics, diagnostics and delivery models. This “new medicine” will create a pathway to more sustainable health care costs and better patient outcomes.

Founded in 2016 by Dr. Boris Nikolic and Julie Sunderland, Biomatics joins with leading innovators and entrepreneurs to translate revolutionary science into the next generation of world-class health care companies.

It’s our goal to seek out radically innovative solutions; we do not invest in traditional drug-discovery, diagnostic or medical-device companies. By combining the best of science with sound investment practices and our operational expertise, we create extraordinary value — for investors and for patients.

Team

No one ever called us traditional, and we’re OK with that. We prefer adjectives like nimble, curious, creative…and often disruptive.

Managing Directors Dr. Boris Nikolic and Julie Sunderland have invested together in emerging technology, health care and life science ventures since 2010. They combine scientific and financial expertise with an established network of leading academics, pharma executives and venture capital firms. Once invested, they take an active role with portfolio companies, supporting startups with hiring, intellectual property, regulatory issues and exit strategy.

Boris Nikolic, M.D.

MANAGING DIRECTOR

Dr. Nikolic is a physician and investor who previously served as chief advisor for science and technology to Bill Gates, leading select for-profit and not-for-profit investment activities. His investments spanned the life science, information technology and health care sectors, including companies such as Foundation Medicine, ResearchGate, Schrodinger and Nimbus Therapeutics. Read More

Julie Sunderland

MANAGING DIRECTOR

Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals. Read More

Liz Birch

INVESTMENT ASSOCIATE

Liz Birch is an Investment Associate at Biomatics where she evaluates pipeline opportunities, undertakes due diligence on investment opportunities and supports portfolio companies. Liz was formerly a Consultant in the Life Sciences practice at L.E.K. Consulting in Boston, where she worked with biopharma clients on strategic and transactional engagements. Read More

Yeon Cramer

BUSINESS OPERATIONS MANAGER

Yeon Cramer is the Business Operations Manager at Biomatics where she manages investor relations and business operations. Before joining Biomatics, Yeon spent six years at Bill Gates’ private office in Seattle (bgC3) working with leaders in communications, energy, health and science on major projects. Read More

Leslie Hepner

PORTFOLIO MANAGER

Leslie Hepner is a Portfolio Manager at Biomatics where she manages portfolio reporting, pipeline development and financial operations. Leslie was formerly a Project Coordinator at the Bill & Melinda Gates Foundation, where she coordinated the investment process for the Program Related Investments (PRI) team, the strategic investment arm of the foundation. Read More

Biomatics Capital’s Dr. Boris Nikolic identified CRISPR as a very powerful game changing technology, after learning of the company through his academic and venture network.

In 2015, the partners of Biomatics played a key role in driving Editas to the next level of growth by leading a $120 million Series B round, marking the largest financial investment to a CRISPR startup. Nikolic joined the board and took an active role in guiding the company to a $94.4 million IPO, which was oversubscribed even in a difficult market.